PRKCD and chronic obstructive pulmonary disease: Recently, several studies using inhibitors for PKCζ/PKCδ (MA130, rottlerin, fisetin, or piscroside C) or an inhibitory peptide against PKCδ reported that PKCs can be useful targets for treating COPD or inflammatory lung diseases [5,23,33,34,35].